

Welch David F
Form 3
January 22, 2019

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Welch David F

(Last) (First) (Middle)

1111 MAIN STREET, SUITE
660

(Street)

VANCOUVER, WA 98660

(City) (State) (Zip)

2. Date of Event Requiring
Statement

(Month/Day/Year)

01/10/2019

3. Issuer Name and Ticker or Trading Symbol
CytoDyn Inc. [CYDY]

4. Relationship of Reporting
Person(s) to Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer ☐ Other
(give title below) (specify below)

5. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group
Filing(Check Applicable Line)
☒ Form filed by One Reporting
Person
☐ Form filed by More than One
Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Common Stock

963,333

I

See Footnote ⁽²⁾

Common Stock

1,675,280

I

See Footnote ⁽³⁾

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)

4. Conversion
or Exercise
Price of

5. Ownership
Form of
Derivative

6. Nature of Indirect
Beneficial
Ownership
(Instr. 5)

Edgar Filing: Welch David F - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Warrant (Right to Buy)	Â ⁽¹⁾	01/28/2021	Common Stock	166,666	\$ 0.75	I	See Footnote ⁽²⁾
Warrant (Right to Buy)	Â ⁽¹⁾	02/16/2023	Common Stock	600,000	\$ 0.75	I	See Footnote ⁽²⁾
Warrant (Right to Buy)	Â ⁽¹⁾	12/28/2023	Common Stock	1,000,000	\$ 0.3	I	See Footnote ⁽²⁾
Warrant (Right to Buy)	Â ⁽¹⁾	09/08/2022	Common Stock	384,615	\$ 0.75	I	See Footnote ⁽³⁾
Warrant (Right to Buy)	Â ⁽¹⁾	09/14/2023	Common Stock	500,000	\$ 0.75	I	See Footnote ⁽³⁾
Convertible Promissory Note	Â ⁽¹⁾	09/28/2019	Common Stock	2,000,000 ⁽⁴⁾	\$ 0.5 ⁽⁵⁾	I	See Footnote ⁽²⁾

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Welch David F 1111 MAIN STREET, SUITE 660 VANCOUVER, WA 98660	Â X	Â	Â	Â

Signatures

/s/ Michael D. Mulholland, as
attorney-in-fact

01/22/2019

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The securities were exercisable on the date of the event which required the filing of this report.

The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA").

(2) David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein.

(3) The reported securities of the Company are held by David Welch Tr Ua 03/02/2000 Welch Charitable Remainder Unitrust Agreement II, for which Dr. Welch is a trustee.

(4) Does not include additional shares issuable upon conversion of accrued interest.

(5) Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.